Bioxel Pharma, Inc. has won its largest paclitaxel order—valued at about $800,000—from a multinational pharmaceutical company that is currently completing Phase III trials for a paclitaxel-based product. Paclitaxel deliveries under the order will be completed in October 2007, with repeat orders expected in the coming months.
Bioxel's paclitaxel will be incorporated in the client's NDA, allowing its use in commercial manufacturing and distribution once the product gains marketing approval. Bioxel estimates that, for its primary indication in the U.S. market, paclitaxel volume requirements could exceed 50 kg annually. Sales and volumes for this client are expected to begin in 2008, in preparation for commercial launch of its NDA product.
"This was a very important win for Bioxel on many levels," said Pascal Delmas, president and chief executive officer of Bioxel Pharma. "This represents repeat business with a customer that has used our paclitaxel product in its previous clinical development. It validates the quality and consistency of our product and the faith that our customers have in Bioxel's ability to deliver on an ongoing commercial basis. Bioxel has proven that it can compete in this market and differentiate itself by offering the highest quality paclitaxel API together with superior customer and regulatory services." Mr. Delmas added, "We have implemented an aggressive marketing push over the past 18 months and this has begun to pay off with substantial orders. We remain committed to the growth of our paclitaxel franchise through customer diversification in both generic and next generation products, as well as through steady geographic expansion."
Magazine
